These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 1035154)

  • 1. Sustained administration of cyclazocine for antagonism of morphine.
    Sullivan MF; Ruemmler PS; Kalkwarf DR
    Drug Alcohol Depend; 1976 Oct; 1(6):415-28. PubMed ID: 1035154
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Assessment of physical dependence in rats after continuous intraperitoneal infusion of morphine or ketocyclazocine [proceedings].
    Howe SJ; McCarthy PS; Metcalf G
    Br J Pharmacol; 1979 Nov; 67(3):427P. PubMed ID: 574041
    [No Abstract]   [Full Text] [Related]  

  • 3. Dissociation of the opioid and nonopioid effects of cyclazocine.
    Calligaro D; Young GA; Khazan N
    Pharmacol Biochem Behav; 1988 May; 30(1):163-7. PubMed ID: 3174740
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vivo and in vitro evaluation of a microencapsulated narcotic antagonist.
    Mason N; Thies C; Cicero TJ
    J Pharm Sci; 1976 Jun; 65(6):847-50. PubMed ID: 932970
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cyclazocine revisited.
    Archer S; Glick SD; Bidlack JM
    Neurochem Res; 1996 Nov; 21(11):1369-73. PubMed ID: 8947927
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Behavioral and morphine-antagonist effects of the optical isomers of pentazocine and cyclazocine.
    McMillan DE; Harris LS
    J Pharmacol Exp Ther; 1972 Mar; 180(3):269-79. PubMed ID: 5012778
    [No Abstract]   [Full Text] [Related]  

  • 7. Effects of morphine, naloxone, d,l-cyclazocine, and d-amphetamine on behaviour controlled by a schedule of interresponse time reinforcement.
    Adam-Carrière D; Merali Z; Stretch R
    Can J Physiol Pharmacol; 1978 Oct; 56(5):707-20. PubMed ID: 709412
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biocompatible implants for the sustained zero-order release of narcotic antagonists.
    Abrahams RA; Ronel SH
    J Biomed Mater Res; 1975 May; 9(3):355-66. PubMed ID: 1176491
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Influence of morphine and cyclazocine on the cortical epileptic foci in rabbits.
    Massotti M; Sagratella S; Argiolas L; Mele L
    Brain Res; 1984 Sep; 310(2):201-12. PubMed ID: 6488016
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of narcotic agonists and antagonists on schedule-induced water and morphine ingestion.
    Leander JD; McMillan DE; Harris LS
    J Pharmacol Exp Ther; 1975 Nov; 195(2):271-8. PubMed ID: 1237618
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An implanted reservoir of morphine solution for rapid induction of physical dependence in rats.
    Goode PG
    Br J Pharmacol; 1971 Mar; 41(3):558-66. PubMed ID: 5103548
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Disposition and metabolism of 3H-cyclazocine in dogs.
    Mulé SJ; Gorodetzky CW; Clements TH
    Adv Biochem Psychopharmacol; 1973; 8(0):503-23. PubMed ID: 4794906
    [No Abstract]   [Full Text] [Related]  

  • 13. The effects of morphine and nalorphine-like drugs in the nondependent, morphine-dependent and cyclazocine-dependent chronic spinal dog.
    Gilbert PE; Martin WR
    J Pharmacol Exp Ther; 1976 Jul; 198(1):66-82. PubMed ID: 945350
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Further characterization of the three-choice morphine, cyclazocine and saline discrimination paradigm: opioids with agonist and antagonist properties.
    White JM; Holtzman SG
    J Pharmacol Exp Ther; 1983 Jan; 224(1):95-9. PubMed ID: 6336785
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A dose ratio comparison of the interaction between morphine and cyclazocine with naloxone in rhesus monkeys on the shock titration task.
    Yaksh TL; Rudy TA
    Eur J Pharmacol; 1977 Nov; 46(2):83-92. PubMed ID: 412680
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Delineation of mu-antagonist, partial kappa agonist and non-opioid agonist activity of cyclazocine using urinary output of rats.
    Leander JD
    Pharmacol Biochem Behav; 1987 Apr; 26(4):705-7. PubMed ID: 3037567
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bias of morphine generalization to cyclazocine by drug history.
    Paule MG; Wenger GR
    Pharmacol Biochem Behav; 1986 Mar; 24(3):479-83. PubMed ID: 3703883
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Self administration: positive and negative reinforcing properties of morphine antagonists in rhesus monkeys.
    Hoffmeister F; Wuttke W
    Adv Biochem Psychopharmacol; 1973; 8(0):361-9. PubMed ID: 4212335
    [No Abstract]   [Full Text] [Related]  

  • 19. Cyclazocine in the treatment of narcotic addiction.
    Jaffe JH
    Curr Psychiatr Ther; 1967; 7():147-56. PubMed ID: 4860298
    [No Abstract]   [Full Text] [Related]  

  • 20. An investigation of the negative-reinforcing properties of naloxone and cyclazocine in squirrel monkeys.
    Stretch R; Pink C; Gervaize P
    Can J Physiol Pharmacol; 1980 Apr; 58(4):384-91. PubMed ID: 6770985
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.